News | July 04, 2025
argenx advances clinical development of agonist antibody for myasthenic syndromes
ARGX-119 is the sixth molecule developed through our Immunology Innovation Program to show proof-of-concept
ARGX-119 is the sixth molecule developed through our Immunology Innovation Program to show proof-of-concept
Eylea 8 mg is the first and only anti-vascular endothelial growth factor (VEGF) treatment in the EU with treatment intervals of up to 6 months for both patients with nAMD and DME
This collaboration ensures that patients receive comprehensive care, including emotional and psychological support throughout their fertility journey
This is the second and final phase of the overall capacity addition of ?195 kL which was under construction at Unit IV Bidar facility
BRAVE study will explore the potential of omaveloxolone to address the critical unmet need of the pediatric FA population
The GMP-compliant facility with automated environmental monitoring accommodates both white room and class 7 and 8 cleanroom space
SUP will obtain regulatory approvals for selling Tiotropium DPI in China
Prasinezumab is a potential first-in-class anti-alpha-synuclein antibody, targeting a known biological driver of Parkinson’s disease progression
The decision to advance subcutaneous and oral amycretin into phase 3 is based on feedback received from regulatory authorities
Now approved for both acute and chronic HCV in adults and children aged 3 and above
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
